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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the selective loss of motor
neurons in the spinal cord, brain stem, and motor cortex. Mutations in superoxide dismutase (SOD1) are associated with
familial ALS and lead to SOD1 protein misfolding and aggregation. Here we show that the molecular chaperone, HSJ1
(DNAJB2), mutations in which cause distal hereditary motor neuropathy, can reduce mutant SOD1 aggregation and improve
motor neuron survival in mutant SOD1 models of ALS. Overexpression of human HSJ1a (hHSJ1a) in vivo in motor neurons of
SOD1G93A transgenic mice ameliorated disease. In particular, there was a significant improvement in muscle force, increased
motor unit number and enhanced motor neuron survival. hHSJ1a was present in a complex with SOD1G93A and led to
reduced SOD1 aggregation at late stages of disease progression. We also observed altered ubiquitin immunoreactivity in
the double transgenic animals, suggesting that ubiquitin modification might be important for the observed improvements.
In a cell model of SOD1G93A aggregation, HSJ1a preferentially bound to mutant SOD1, enhanced SOD1 ubiquitylation and
reduced SOD1 aggregation in a J-domain and ubiquitin interaction motif (UIM) dependent manner. Collectively, the data
suggest that HSJ1a acts on mutant SOD1 through a combination of chaperone, co-chaperone and pro-ubiquitylation
activity. These results show that targeting SOD1 protein misfolding and aggregation in vivo can be neuroprotective and
suggest that manipulation of DnaJ molecular chaperones might be useful in the treatment of ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, adult-onset
neurodegenerative disorder characterized by the selective loss of
upper and lower motor neurons in the brain and spinal cord. The
loss of motor neurons results in progressive paralysis and death,
typically within 5 years of onset [1]. Most cases of ALS are
sporadic and of unknown cause (sporadic ALS, or sALS), however,
in around 10% of cases the disease is inherited (familial ALS, or
fALS). Of these, approximately 20% have been attributed to
mutations in the gene encoding superoxide dismutase 1 (SOD1)
[2]. Several potential disease mechanisms have been proposed for
mutant SOD1 mediated motor neuron cell death [3,4]; however,
the critical initiators and accelerators of motor neuron degener-
ation remain elusive.
A hallmark of many neurodegenerative diseases, including ALS,
is the formation of ubiquitin positive inclusions of aggregated
protein. Intracellular proteinaceous inclusions, evident in the
motor neurons of ALS patients [5,6,7] and also in mutant SOD1
mice [8,9], represent an important feature of ALS. The
accumulation of misfolded and aggregation-prone protein suggests
an imbalance of protein homeostasis (proteostasis). Molecular
chaperones are critical factors for maintaining proteostasis through
facilitating protein folding and quality control [10]. Indeed, the
heat shock response co-inducer arimoclomol, which upregulates
molecular chaperone expression, can protect against mutant
SOD1 toxicity in vivo [11,12]. The manipulation of several
individual molecular chaperones and co-chaperones, including
small Hsps (HSPB1, HSPB5, HSPB8), Hsp70 (HSPA1), DNAJB1,
CHIP and BAG1 have all been shown to reduce mutant SOD1
aggregation and/or improve viability in cells [13,14,15,
16,17,18,19]. However, the upregulation of individual chaperones
in vivo has been less successful, as only HSPB1 provided some
protective effects at an early phase in the mutant SOD1G93A
model of ALS, but not at late stage of the disease [17,20].
Overexpression of either HSPA1 or BAG1 had no beneficial
effects in mouse models of ALS [15,18].
The molecular chaperone HSJ1 (DNAJB2) is a member of the
Hsp40 (or DnaJ) family of heat shock proteins that contain a J
domain, which is crucial in substrate recognition by Hsp70
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[21,22,23]. Thus, Hsp40/DnaJ protein function is essential for
Hsp70 function, including protein folding and directing misfolded
proteins towards the proteasome [23]. HSJ1 is preferentially
expressed in neurons as two alternatively spliced isoforms that
differ in their subcellular localisation [21,24]. The smaller
cytoplasmic isoform, HSJ1a (DNAJB2a), can suppress the
aggregation of polyglutamine expanded proteins [25,26,27,28],
through a mechanism dependent on the regulation of the Hsp70
ATPase cycle by its J domain and enhancing proteasomal
degradation of misfolded client proteins via its ubiquitin interac-
tion motif (UIM) domains [25]. HSJ1a can also co-operate with
Hsp70 to regulate the proteasomal targeting of the spinocerebellar
ataxia type 3-linked protein, ataxin 3 [29]. Transgenic upregula-
tion of HSJ1a in a mouse model of Huntington’s disease reduced
huntingtin aggregation and improved neurological performance
by reducing the ability of aggregated huntingtin to promote
further aggregation [28]. Furthermore, HSJ1 appears to be critical
for normal motor neuron function, as mutations in DNAJB2 cause
recessive distal hereditary motor neuropathy (dHMN) [30]. The
potential importance of HSJ1 for motor neuron function was
further demonstrated in a cell model of ALS, in which
overexpression of HSJ1a or HSJ1b reduced inclusion formation
by the A4V mutant of SOD1 [30].
Therefore, it is possible that enhanced expression of HSJ1a
alone might be beneficial in mutant SOD1 induced ALS and
could modify SOD1 proteostasis and/or enhance motor neuron
function in ALS. In this study, we investigated the ability of HSJ1a
to protect against mutant SOD1G93A in vivo and in cells. Using a
transgenic approach, we expressed human HSJ1a in mice that
overexpress the SOD1G93A mutation and assessed physiological
function at a late stage of disease to test whether upregulation of
HSJ1a can have beneficial effects in this model of ALS. We also
assessed the effects of HSJ1a upregulation on spinal cord motor
neuron survival and identified interactions between mutant SOD1
protein and HSJ1a in both spinal cords of transgenic mice and in a
cell model. Our results show that HSJ1a reduces mutant SOD1
aggregation dependent on its J and UIM domains and can
enhance late stage motor neuron survival in a mouse model of
SOD1 ALS.
Results
hHSJ1a expression in SOD1G93A mice
HSJ1a transgenic mice were produced that express human
HSJ1a (hHSJ1a) under the control of the bovine prion protein
promoter. Female hemizygous hHSJ1a and male hemizygous
SOD1G93A (G93A) mice [31] were then crossed to generate
double transgenic (DBLE) mice. These DBLE mice were
compared with littermate G93A, wild type (WT) and hemizygous
hHSJ1a only (hHSJ1a) animals. hHSJ1a expression in the spinal
cord was assessed by Western blotting and immunohistochemistry
(Figure 1A and 1C). The expression of hHSJ1a was approximately
seven-fold the endogenous mouse HSJ1a and was relatively
constant at 60 and 90 days, but was reduced at 120 days of age
(Figure 1B). The constant expression in this line, line 61a, is in
contrast to another hHSJ1a transgenic line, line 52a, which
showed a three-fold increase in expression between 30 and 105
days of age [28]. Immunohistochemistry of 120 day lumbar spinal
cord confirmed that the increase in HSJ1a staining in the hHSJ1a
and DBLE animals was predominantly originating from motor
neurons (Figure 1C). This suggests that the reduction in hHSJ1a
expression in the DBLE spinal cords at 120 days is likely to reflect
a reduction in the number of surviving motor neurons due to
SOD1G93A toxicity, but might also reflect a reduction in promoter
activity or hHSJ1a stability.
hHSJ1a overexpression does not alter the decline in body
weight during disease progression in SOD1G93A mice
Littermate mice from each experimental group (WT, hHSJ1a,
G93A and DBLE) were monitored for loss of body weight
throughout the study. As previously reported [32], G93A mice
started to lose weight from 90 days compared to WT and hHSJ1a
mice. Weight loss in female (Figure 2A) and male (Figure 2B)
DBLE transgenic mice expressing SOD1G93A and hHSJ1a was
Figure 1. hHSJ1a expression in spinal cord. (A) Representative
Western blot showing total levels of HSJ1 expression in G93A and DBLE
transgenic animals at 60, 90 and 120 days of age using anti-HSJ1
antibody (S653). Note the human HSJ1a (hHSJ1a) transgene band
running just above endogenous mouse HSJ1a (mHSJ1a) and below
mouse HSJ1b (mHSJ1b). (B) hHSJ1a levels in spinal cords were analysed
by densitometry and normalised to mHSJ1a (left panel) or mHSJ1b
(right panel). Mean relative expression was plotted 6SEM for each age
group (n$4; *p,0.05). (C) Representative images of anti-HSJ1a (16321)
immunohistochemistry in thoracic region of spinal cords of WT, hHSJ1a,
G93A and DBLE transgenic mice at 120 days of age confirming hHSJ1a
expression in motor neurons. Scale bar: 20 mm.
doi:10.1371/journal.pone.0073944.g001
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very similar to G93A littermates and no significant effect on the
loss of bodyweight was observed.
hHSJ1a overexpression improves muscle function in late
stage SOD1G93A mice
At 120 days of age, female mice of all genotypes were
anaesthetized and underwent in vivo assessment of neuromuscular
function, including i) assessment of maximum force production in
the tibialis anterior (TA) and extensor digitorum longus (EDL)
muscles, ii) evaluation of muscle contractile characteristics and iii)
assessment of the number of surviving functional motor units
innervating the EDL muscle. Similar to previous reports [11,33],
by 120 days the TA and EDL muscles in G93A mice produced
approximately 90% and 60% less force than that produced by TA
and EDL muscles respectively in WT mice (Figure 3A, B).
However, in SOD1G93A mice overexpressing HSJ1a there was a
significant preservation of muscle force production, such that TA
muscles of DBLE mice were capable of producing 23.962.4 g
force, compared to 9.961.8 g produced by G93A TA muscles
(p,0.001; Figure 3A). In EDL muscles there was also an
improvement in muscle force production in DBLE mice as these
mice were capable of exerting 18.761.1 g force, compared to
11.062.1 g in G93A mice (p,0.01; Figure 3B).
TA and EDL are fast twitch muscles that normally contract and
relax rapidly. However, as a result of the selective loss of motor
neurons that innervate fast twitch type IIa muscles fibres in G93A
mice as disease progresses, the contractile characteristics of TA
and EDL alter, and these fast twitch muscles begin to resemble
slow twitch muscles, with a decrease in the speed of muscle
contraction [11,32,33]. Thus, in G93A mice, the time taken by
both TA and EDL to reach maximum twitch force (time to peak;
TTP) was significantly slower than in WT mice (Figure 3C, D). In
contrast, in EDL muscles of DBLE mice, the TTP was significantly
faster than in G93A EDL muscles and was similar to that in WT
mice (TTP in G93A EDL muscles = 55.062.0 msec; TTP in
DBLE=49.161.3 msec compared to TTP in WT=
45.461.6 msec, p,0.05 Figure 3D). Although, the TTP of TA
in DBLE mice was also faster than in G93A, this improvement did
not reach statistical significance (Figure 3C).
Overexpression of hHSJ1a improves the survival of
functional motor units in SOD1G93A mice
The number of functional motor units innervating EDL muscles
was then assessed in vivo in mice of each experimental group.
Typical motor unit recordings for each experimental group are
shown in Figure 4A. Assessment of the number of motor units
revealed that overexpression of hHSJ1a alone had no effect on
motor unit number compared to WT (Figure 4B). However, in
G93A mice by 120 days of age there is a significant reduction in
the number of surviving motor units innervating the EDL, such
that only 7.060.8 motor units survive in G93A mice, compared to
29.061.3 in EDL of WT mice (p,0.001 4B). Importantly, in
DBLE mice there was a 57% increase in EDL motor unit survival
compared to the G93A (DBLE=11.061.1; p,0.05). These results
show that increased hHSJ1a expression protects functional motor
units in vivo from mutant SOD1G93A toxicity.
Overexpression of hHSJ1a improves muscle weight and
increases motor neuron survival, but has no effect on
lifespan of SOD1G93A mice
At the end of the physiological assessment of muscle force, the
TA and EDL muscles were removed and weighed in order to
determine the extent of muscle mass. As expected, in G93A mice
there was a significant reduction in the weight of the TA and EDL
muscles compared to WT mice (Figure 3E, F). In DBLE mice, TA
muscle weights mice were not significantly greater than in G93A
mice (Figure 3E); however, the EDL muscles from DBLE animals
weighed significantly more than in mice expressing SOD1G93A
alone (Figure 3F; 6.360.7 mg in G93A and 8.160.5 mg in DBLE
EDL; p,0.05).
Following removal of the hindlimb muscles, the animals were
perfused with fixative and the lumbar spinal cord removed and
processed for determination of motor neuron survival. Motor
neurons within the sciatic motor pool were identified in the ventral
horn of the lumbar cord (between the lumbar regions L2–L6)
using morphological criteria (examples shown in Figure 4C). As
can be seen in Figure 4D, and in line with previous reports
[11,33], the number of motor neurons in the spinal cord of G93A
mice was dramatically less than in either WT or hHSJ1a mice
(WT=460620; hHSJ1a= 435610 compared to 155615 in
G93A; p,0.001 Figure 4D). However, in DBLE transgenic mice
expressing hHSJ1a and SOD1G93A, there was a 61% increase in
motor neuron survival compared to G93A mice (250610;
p,0.001). These morphological data reflect those of motor unit
survival (Figure 4B), and confirm that hHSJ1a overexpression
protects motor neurons against mutant SOD1G93A toxicity at 120
days of age.
Given these improvements in motor neuron survival and muscle
function at a relatively late stage of disease, we hypothesised that
the effect of HSJ1a expression may be more pronounced earlier in
disease. To test this hypothesis, motor neurons within the sciatic
Figure 2. hHSJ1a does not affect the bodyweight of SOD1G93A
mice. (A) Female and (B) male WT, (white line) hHSJ1a (grey dotted),
G93A (grey line) or DBLE (black dotted) mice were weighed at least
twice weekly from 70–120 days of age. The mean bodyweight 6SEM is
shown (n$7).
doi:10.1371/journal.pone.0073944.g002
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motor pool of female mice were counted at 90 days of age. The
G93A mice had significantly fewer motor neurons compared to
WT (67% of WT level, p,0.05; Figure 5A). Surprisingly, the
DBLE mice had a similar reduction in motor neurons suggesting
that hHSJ1a expression does not improve motor neuron survival
at 90 days, and the beneficial effects are only evident late in
disease. Furthermore, analysis of lifespan of male G93A and
DBLE mice revealed that overexpression of HSJ1a had no
significant effect on the lifespan of SOD1G93A mice (Figure 5B).
hHSJ1a forms a complex with SOD1 and reduces SOD1
aggregation in vivo
As overexpression of hHSJ1a protected spinal cord motor
neurons and improved muscle function in vivo in a model of
SOD1G93A ALS, we hypothesised that the protective effect of
hHSJ1a in motor neurons might be a result of reducing SOD1
aggregation. The levels of SOD1 protein in the spinal cord of male
mice were analysed using the C4F6 antibody that recognizes a
misfolded conformation of the SOD1 protein [34,35]. Analyses of
Figure 3. hHSJ1a expression improves muscle characteristics in SOD1G93A mice. Female mice were assessed at 12065 days. (A) Maximal
tetanic force generated by the tibialis anterior (TA) muscle (n$8). (B) Maximal tetanic force generated by the extensor digitorum longus (EDL) muscle
(n$10). (C) Time to peak (TTP) force for the TA muscle was increased in G93A animals, and in (D) EDL this increase in TTP was partially reduced in
DBLE (n$10). (E) Mean weight of the TA and (F) EDL muscles (n = 12). All graphs show the mean 6SEM, (***p,0.001**p,0.01, *p,0.05).
doi:10.1371/journal.pone.0073944.g003
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total spinal cord lysates from each genotype confirmed that levels
of SOD1 increased as disease progressed in both the G93A and
DBLE animals, and hHSJ1a expression did not alter the total level
of SOD1 at any stage (Figure 6A). We then used non-reducing
SDS-PAGE to monitor the formation of SOD1 aggregates and
observed that higher molecular weight (HMW) species that were
trapped at the top of the gel, in the stacking gel and in the loading
well accumulated as disease progressed from 60 to 120 days.
Interestingly, in the DBLE spinal cords there appeared to be less
HMW material trapped at the stacking gel and in the well
(Figure 6B). To analyse these potential aggregates further, a
differential sedimentation protocol of spinal cord lysates was
developed to separate soluble protein from sedimentable, aggre-
gated, insoluble protein. Analysing these fractions by Western
blotting with C4F6 confirmed that insoluble, aggregated SOD1
accumulated as disease progressed. Importantly, the amount of
insoluble SOD1 was significantly reduced in the DBLE spinal
cord, but only at 120 days of age, not at earlier stages of disease
(Figure 6C). To test the hypothesis that HSJ1a could be acting
directly on SOD1, co-immunoprecipitation with C4F6 was used to
detect potential HSJ1a:SOD1 complexes. hHSJ1a only precipi-
tated with SOD1 from the DBLE tissue and the reciprocal
precipitation confirmed that SOD1 could only be recovered with
HSJ1a from the DBLE spinal cords (Figure 6D). Interestingly,
mHSJ1a and mHSJ1b were not detected in the C4F6 precipitation
only hHSJ1a, despite the higher levels of mHSJ1b in the cell
lysates. This suggests that either HSJ1a preferentially binds mutant
SOD1, or that the heterologously expressed hHSJ1a protein is
more available to bind mutant SOD1 than endogenous HSJ1
proteins.
The localisation of SOD1 misfolding in tissue was investigated
using an antibody to the SOD1 exposed dimer interface (SEDI)
[36]. No staining was observed in the absence of SOD1G93A
overexpression, for example in the WT spinal cord. There was
intense punctate staining in some motor neurons in the G93A
spinal cords, as previously described [36]. Motor neurons were
also immunoreactive for SEDI in the DBLE animals but the
intensity of staining appeared to be reduced (Figure 7A),
supporting the notion that there was less misfolded aggregated
SOD1 present following hHSJ1a expression.
hHSJ1a alters ubiquitylation in the spinal cord
HSJ1 expression has been shown to enhance protein ubiquityla-
tion and HSJ1a can preferentially bind to ubiquitylated polyglu-
tamine expanded huntingtin in mouse brain [25,28], therefore, we
tested the hypothesis that altered ubiquitylation could be
mediating the reduction in SOD1 aggregation and enhanced
motor neuron survival. Immunofluorescence of spinal cords with a
pan-ubiquitin antibody revealed enhanced diffuse ubiquitin
immunoreactivity in motor neuron cell bodies and processes
Figure 4. hHSJ1a expression improves motor unit and motor neuron survival in SOD1G93A mice. (A) Typical examples of motor unit
traces are shown from the EDL muscle of WT, hHSJ1a, G93A and DBLE female mice. (B) The mean motor units in the EDL muscle 6SEM are shown in
the bar chart (n$10; ***p,0.001, *p,0.05). (C) Typical histological staining of a lumbar spinal cord section of 120 day WT, hHSJ1a, G93A and DBLE
female mice. Sections were stained with gallocynanin. Inset shows magnification of boxed area. Scale bar 200 mm. (D) Serial gallocynanin stained
sections of the L2–L6 region of 120 day spinal cord were analysed under light microscopy and motor neurons counted. The bar chart shows the mean
motor neuron number 6SEM (n= 3; ***p,0.001, **p,0.01).
doi:10.1371/journal.pone.0073944.g004
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compared to G93A spinal cord, where punctate ubiquitin
immunoreactivity characteristic of inclusions was observed
(Figure 7B). These data suggest that HSJ1a mediated a reduction
in SOD1 aggregation in motor neurons late in the disease process
through a mechanism potentially involving ubiquitylation and that
this delays motor neuron cell death.
HSJ1a reduces SOD1G93A aggregation in a cell model
To probe the potential mechanisms and domain requirements
of the hHSJ1a mediated reduction in SOD1 aggregation and
improved motor neuron survival in the SOD1G93A mouse model
of ALS, we developed a cell model of SOD1G93A aggregation
based on the expression of GFP tagged SOD1 (GFP-SOD1) in
SK-N-SH neuroblastoma cells, which do not express detectable
endogenous HSJ1. Wild-type SOD1 (SOD1-WT) was evenly
distributed throughout the cytoplasm and nucleus in over 95% of
cells and was present in only the soluble protein fraction following
sedimentation analyses (Figure 8A–C). In contrast, SOD1G93A
(SOD1-G93A) formed perinuclear inclusions in approximately
40% of cells and had a substantial insoluble fraction on
sedimentation (Figure 8A–C). The expression of HSJ1a led to a
significant reduction in SOD1-G93A inclusions and redistribution
to an even cytoplasmic and nuclear staining pattern similar to the
SOD1-WT. Furthermore, HSJ1a expression reduced the insoluble
sedimentable component of SOD1-G93A. To test if the ability of
HSJ1a to reduce SOD1-G93A aggregation was dependent on the
J or UIM domains, we used a point mutation in the J domain that
disrupts the interaction with Hsp70 (H31Q) or 4 point mutations
that disrupt the function of the UIM domains (S219A/E222A/
S262A/E265A) (DUIM) [25]. The J domain mutant H31Q lost
the ability to suppress SOD1-G93A aggregation and inclusion
formation, whereas the UIM mutant was partially functional, as it
could still reduce aggregation and inclusion formation, but was not
as efficient as wild-type HSJ1a. The interaction of HSJ1a with
SOD1-WT and SOD1-G93A was compared by reciprocal co-
immunoprecipitation (Figure 8D). HSJ1a bound preferentially to
the mutant form of SOD1, although there was some detectable
binding to SOD1-WT. The H31Q and DUIM mutants of HSJ1a
retained the ability to bind SOD1-G93A. In fact, their binding was
stronger than wild-type HSJ1a, suggesting that these mutants bind
the misfolded client protein non-productively.
HSJ1a enhances SOD1G93A ubiquitylation
The potential of HSJ1a to alter SOD1 ubiquitylation was
investigated further using the cell model. Triple label immunoflu-
orescence revealed that both HSJ1a and ubiquitin were recruited
to SOD1-G93A inclusions following proteasome inhibition with
MG132 (Figure 9A). To test whether the mutant SOD1 was a
target for HSJ1a mediated ubiquitylation, SOD1-G93A was
immunoprecipitated with antibody C4F6 from cells co-transfected
with HSJ1a, the J domain mutant H31Q, or the UIM mutant and
blotted for ubiquitin (Figure 9B). The expression of HSJ1a or
H31Q led to a small increase in HMW ubiquitin immunoreac-
tivity in the cell lysate input, especially in the presence of
proteasome inhibition as previously described [25]. In the absence
of proteasome inhibition, the HMW ubiquitin immunoreactive
smear in the C4F6 purified material was most pronounced in the
cells transfected with the H31Q mutant. In contrast, proteasome
inhibition revealed a strong increase in the C4F6 purified HMW
ubiquitin immunoreactivity in the HSJ1a co-transfected cells
(Figure 9B), suggesting that HSJ1a was enhancing mutant SOD1
ubiquitylation and stimulating its removal by the proteasome. The
HSJ1a DUIM mutant did not enhance SOD1-G93A ubiquityla-
tion, confirming that this effect was dependent on HSJ1a UIM
domains.
Discussion
ALS is recognized as a multifactorial disease with a range of
pathways and cell types affected, leading to the demise of motor
neurons and ultimately paralysis of muscles and death. The
aggregation of mutant SOD1 has been implicated in the
pathogenesis of fALS and the upregulation of molecular chaper-
ones can protect against SOD1G93A mediated motor neuron cell
death [11,12]. The upregulation of individual molecular chaper-
ones, although effective in cell models, has been less effective in
animal models [15,17,18]. This has led to the suggestion that
upregulation of several chaperones is probably more effective than
individual chaperones alone [37], and that protection may even
require several chaperone machines. Here, we have shown that
overexpression of HSJ1a can reduce SOD1 aggregation and
improve motor neuron survival. This suggests that some molecular
chaperones may be more effective than others at reducing protein
aggregation and maintaining proteostasis in motor neurons.
Figure 5. hHSJ1a expression does not improve motor neuron
survival at 90 days or lifespan of SOD1G93A mice. (A) Serial
gallocynanin stained sections of the L2–L6 region from 90 day old
spinal cord from female mice were analysed under light microscopy and
motor neurons counted. The bar chart shows the mean motor neuron
number 6SEM (n= 3; *p,0.05). (B) Mean survival of male G93A and
DBLE mice is shown (n$11). Overexpression of hHSJ1a had no effect on
the lifespan of SOD1G93A mice.
doi:10.1371/journal.pone.0073944.g005
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HSJ1 is a member of a subfamily of DNAJB proteins that are
particularly effective at preventing polyglutamine aggregation
[38], but HSJ1 is unique in that it also contains two UIM domains
that can bind ubiquitin [25]. HSJ1a overexpression reduced
mutant huntingtin aggregation in mouse brain in a manner that
was dependent on its J domain and UIM domains [28]. In the case
of mutant SOD1, the J domain was also needed to reduce SOD1
aggregation in cells, suggesting a role for Hsp70. The J domain
mutant could still bind to mutant SOD1 but the binding appears
to be non-productive and suggests that HSJ1a co-operates with
Hsp70 to actively prevent mutant SOD1 aggregation, rather than
by a passive chaperone action. The involvement of the UIM
domains of HSJ1a in protecting against mutant SOD1 was less
clear, as the UIM mutant retained some partial activity, but was
Figure 6. hHSJ1a reduces levels of aggregated SOD1 in spinal cord. (A) Representative Western blot with anti-SOD1 (C4F6) of spinal cord
lysates from male transgenic animals of indicated age resolved under reducing conditions. Mutant SOD1 levels were quantified by densitometry,
expressed relative to b-tubulin and plotted as mean 6SEM for G93A (light grey) and DBLE (black) bars data from at least four independent spinal
cords per group. (B) Representative Western blots of spinal cord lysates from indicated ages of male mice with anti-SOD1 (C4F6) resolved by SDS-
PAGE in non-reducing conditions. Note the decrease in higher molecular weight (HMW) oligomers of SOD1 in DBLE spinal cords. The position of
molecular weight markers in indicated on the left in kDa (C) Representative Western blots of total, soluble and insoluble SOD1 following differential
sedimentation resolved by reducing SDS-PAGE from G93A and DBLE transgenic male animals at the ages indicated stained with anti-SOD1 (C4F6)
confirmed the age dependent increase in detergent insoluble SOD1 which was reduced by overexpression of hHSJ1a. Levels of pelleted detergent-
insoluble SOD1 were measured by densitometry based on at least four independent spinal cords and plotted as mean 6SEM for G93A (light grey)
and DBLE (black) bars for each age group (n$4; *p,0.05). (D) hHSJ1a associates with SOD1 in spinal cords of DBLE transgenic male animals. Western
blots of reciprocally immunoprecipitated material (IP) probed for HSJ1 and SOD1. IPs were performed from WT, hHSJ1a, G93A and DBLE transgenic
spinal cord lysates at 120 days of age with anti-HSJ1 (S653), SOD1 (C4F6) or control antibodies (IgG), as indicated. Asterisk denotes non-specific band
that is characteristic for the antibody combination used.
doi:10.1371/journal.pone.0073944.g006
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compromised relative to wild-type HSJ1a. We were not able to
investigate the role of the J domain or UIM domain in the
suppression of mutant SOD1 aggregation in vivo because of the
relatively low recovery of mutant SOD1 by immunoaffinity
purification techniques compared to mutant huntingtin [28]. In
a cell model of mutant SOD1 aggregation, however, HSJ1a
stimulated SOD1G93A ubiquitylation and proteasomal degrada-
tion in a UIM dependent manner, suggesting that the altered
ubiquitin immunoreactivity observed in the DBLE animals might
be involved in the protective mechanism in vivo. Collectively, the
data suggest that the combination of the different HSJ1a domains
function together as a chaperone, cochaperone and pro-ubiqui-
tylation factor to reduce mutant SOD1 aggregation. It is also
possible that other members of this DNAJB subfamily of proteins
that lack the UIM domain, but are effective against polyglutamine
aggregation, may also be effective against mutant SOD1 in cells
and in vivo.
In addition to the potential specialisation of certain chaperone
anti-aggregation properties, it is likely that some chaperones are
more important for motor neuron function and maintenance than
others. In particular, mutations of some small heat proteins
(HSPB1 and HSPB8) lead to dHMN and Charcot-Marie Tooth
(CMT2) disease [39]. HSJ1 proteins are also important for motor
neuron function or maintenance, as mutations in DNAJB2 leads to
motor neuropathy in man [30]. Whether the critical role of HSJ1
proteins is to prevent protein aggregation or deal with motor
neuron specific client proteins still remains to be determined, but it
is possible that a loss of HSJ1 chaperone activity could lead to
enhanced aggregation of SOD1 or other proteins that could
ultimately contribute to motor neuron cell death. This will need to
be tested in animal models of HSJ1 loss of function to identify
what the cellular consequences are of HSJ1 ablation for motor
Figure 7. hHSJ1a alters ubiquitylation in SOD1G93A spinal cord.
(A) Immunohistochemistry with SEDI anti-SOD1 antibody on 120 day
lumbar spinal cord from female mice showed no reactivity in WT tissue
and punctate staining in G93A and DBLE. Scale bar 50 mm (B)
Immunofluorescence of G93A or DBLE 90 day spinal cord from female
mice, as indicated, showed enhanced ubiquitin staining (green) in
motor neuron cell bodies and processes labelled with bIII tubulin
antibody (red). Nuclei were stained with DAPI visible in MERGE panel.
Scale bar 20 mm.
doi:10.1371/journal.pone.0073944.g007
Figure 8. HSJ1a reduces inclusion formation in SK-N-SH cells. (A) Representative images of wild type (SOD1-WT) or SOD1G93A mutant GFP-
SOD1 (SOD1-G93A) localisation in transfected cells in the absence or presence of HSJ1a. Scale bars: 10 mm. (B) Incidence of inclusion positive cells
determined by counting more than 400 cells per transfection condition in three independent experiments. Mean values 6SEM plotted for each
group (*p,0.05, *** p,0.001). (C) Representative Western blots using anti-SOD1 (SOD-100) of SOD1 WT or G93A from total cell lysates (Total)
compared to the soluble fraction (Soluble) or sedimented insoluble fraction (Insoluble) following differential sedimentation in the presence or
absence of HSJ1a, HSJ1a J domain mutant (H31Q) or UIM mutant (DUIM). (D) Western blots with anti-SOD1 (SOD-100) or anti-HSJ1 (S653) showing
reciprocal co-immunoprecipitation (IP) of SOD1 (anti-GFP) or anti-HSJ1a (anti-myc). HSJ1a had a higher recovery with SOD1-G93A compared to SOD1-
WT. There was no co-precipitation with control non-specific antibody (IgG).
doi:10.1371/journal.pone.0073944.g008
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neuron biology. Similarly, overexpression of other dHMN or
CMT2 chaperones may be beneficial for motor neuron survival.
HSPB1 showed effects early, but not late, in disease [17,20], and
therefore might be complementary to HSJ1a overexpression. Such
that a combination of the two chaperones could yield better
protection. HSPB8 has yet to be tested in mouse models of fALS,
although it is potentially a potent chaperone against fALS related
proteins [19].
The overexpression of hHSJ1a improved motor neuron survival
and muscle function in the SOD1G93A mouse model, but did not
prevent the SOD1G93A mediated loss of body mass. Weight loss is
a major determinant of the endpoint applied in our ethically
approved protocols to reduce animal suffering, therefore, it is
perhaps not surprising that we also did not observe any increase in
lifespan in the DBLE mice. The lack of lifespan extension, or body
mass retention, commensurate with the improved neuromuscular
performance could reflect the relatively late effects we observed on
SOD1 aggregation and motor neuron survival. Since HSJ1 is part
of a larger chaperone complex, it is possible that increasing the
expression of one chaperone from the complex cannot exert
sufficient chaperone activity to fully correct protein misfolding in
ALS. Thus, the reduction in SOD1 aggregation we observed may
not be sufficient to protect motor neurons and neuromuscular
function in the longer term and increase the lifespan of these mice.
Reduced aggregation and increased motor neuron survival were
only detectable close to end stage and the disease in this aggressive
model may have been too advanced by this point to be delayed. It
is unclear why the effect of hHSJ1a on SOD1 aggregation was
only observed late in disease, as the level of hHSJ1a was relatively
constant. This is unlike the case of mutant huntingtin and hHSJ1a
line 52a where we observed a good spatiotemporal correlation
between the level of hHSJ1a and reduction in mutant huntingtin
aggregation [28]. It is possible that in vivo the mutant SOD1 is not
fully accessible for HSJ1a chaperone activity until later in disease,
either through a change in conformation or a post-translational
modification, such as ubiquitylation. Alternatively, HSJ1a might
only bind certain conformations of SOD1, similar to the way it
prefers to bind high molecular weight complexes of mutant
huntingtin [28], and that these species increase as the disease
progresses. Interestingly, the proportion of mutant SOD1 that was
Figure 9. hHSJ1a enhances SOD1G93A ubiquitylation. (A) Representative immunofluorescence image showing co-localization of mutant GFP-
SOD1 (SOD1-G93A, green), myc-HSJ1a (S653, red) and myc-ubiquitin (pan Ub, blue) within an intracellular inclusion (arrowed) in SK-N-SH cells,
following co-transfection and proteasome inhibition with MG132. Scale bar: 10 mm. (B) Western blots with anti-SOD1 (C4F6 or SOD100), anti-HSJ1
(S653) and pan-ubiquitin (Ub) antibody as indicated, showing input and C4F6-immunoprecipitated material from SK-N-SH cells transfected and
treated with MG132 as indicated. An increase of ubiquitin reactivity of in the presence of WT HSJ1a was observed upon proteasome inhibition. The
HSJ1a H31Q mutant did not stimulate proteasomal degradation of ubiquitylated SOD1, whereas the HSJ1a DUIM mutant did not stimulate SOD1-
G93A ubiquitylation. Asterisks indicate IgG bands. The position of molecular weight markers is indicated on the left.
doi:10.1371/journal.pone.0073944.g009
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insoluble increased between 90 and 120 days and this might reflect
a change in the type of SOD1 aggregates or a failure of the cellular
machinery to deal with the mutant protein later in disease. The
effect of hHSJ1a on SOD1 is likely to be direct as hHSJ1a is
present in a complex with SOD1 in DBLE spinal cord. Although
both HSJ1a and HSJ1b have been reported to reduce SOD1A4V
inclusion formation in cells [30], mHSJ1b was not detected in the
SOD1 complex suggesting that HSJ1a might be more efficient
against mutant SOD1 in vivo. It was not possible to determine the
composition of the HSJ1a: SOD1 complexes and whether they
were monomeric, oligomers or aggregates. Nonetheless, the
improved survival of motor neurons suggests that the SOD1
species targeted by HSJ1a are part of the pathological process and
potentially important targets for chaperone based therapies.
In conclusion, our results show that over expression of HSJ1a
ameliorates several disease signs at a late stage of disease
progression in the SOD1G93A mouse model of ALS. The late
action of HSJ1a suggests that if methods could be developed for
upregulating HSJ1a expression in motor neurons it could
potentially be of benefit post-symptom onset. The data also
confirm that reducing protein aggregation can lead to improve-
ments in motor neuron survival and suggest that therapies aimed
at improving protein quality control may enhance neuronal
survival in ALS.
Materials and Methods
Ethical statement
All experiments were carried out under license from the UK
Home Office in accordance with the Animals (Scientific Proce-
dures) Act 1986 and following approval from the Institute of
Neurology Ethical Review Committee. All surgery was performed
under anaesthesia, efforts were made at all stages to minimize
suffering, including the use of humane end points.
Primary antibodies
HSJ1 antibody (S653) and anti-HSJ1a (16321) were generated
as described [24] and affinity purified, SOD-100 was from Assay
Designs (Ann Arbor, Michigan, USA), SEDI conformational
antibody was a kind gift of Janice Roberston and Avi Chakrabartty
(University of Toronto, Canada). C4F6 SOD1 antibody was a
kind gift of Makoto Urushitani (Shiga University of Medical
Science, Japan), GFP antibody was from Roche (Burgess Hill,
West Sussex, UK), b-III-tubulin antibody was from Covance
(Maidenhead, Berkshire, UK), pan-ubiquitin antibody was from
Dako (Ely, Cambridgeshire, UK). c-Myc (clone 9E10) and b-
tubulin antibody (clone TUB2.1) were from Sigma-Aldrich (Poole,
Dorset, UK).
Production of human HSJ1a transgenic mice
The hHSJ1a transgene PrP-hHSJ1a-poly(A) was created by
cloning the bovine PrP promoter fragment [40] upstream of the
hHSJ1a cDNA open reading frame [24] with a simian virus 40
poly(A) sequence. An 8 kb linearised, gel purified fragment in
injection buffer (10 mM Tris-HCl pH 7.4, 0.25 mM EDTA) at
50 ng/ml was used for pronuclear injection of B6/CBA F1
blastocysts by Dr Jose Gonzalez (EMBL), with subsequent founder
generation. Founders were screened by PCR using hHSJ1 specific
primers F3 (59-CAA TCA ATG GTG TCC CAG ATG ACC
TGG-39) and R3 (59-CCA CAA CTA GAA TGC AGT G-39).
Positive founders were crossed to C57Bl/6 animals. The hHSJ1a
line 61a was derived and hHSJ1a expression confirmed, then
backcrossed onto a C57Bl/66SJL background for use in this
study.
Mouse maintenance and breeding
All animals were maintained at the Denny Brown Laboratories,
UCL Institute of Neurology, London, UK. Mice were housed at
2161uC with relative humidity 55610% and maintained on a 12-
hour light/dark cycle with access to food (standard pellets) and
water provided ad libitum via an overhead rack. At the onset of
hindlimb paralysis, affected animals were provided with food
pellets soaked in water at ground level to ensure sufficient
nourishment and hydration. Transgenic mice expressing human
SOD1G93A mutant protein (TgN[SOD1G93A]1Gur; Jackson Lab-
oratories, Bar Harbour) [31] were maintained by breeding male
heterozygous carriers with female (C57BL/66SJL) F1 hybrids.
Crossing males heterozygous for SOD1G93A mutant protein to
females heterozygous for hHSJ1a transgene generated offspring of
four genotypes used in this study. The presence of the SOD1G93A
mutation and hHSJ1a transgene was confirmed by PCR reaction
from ear biopsies in all mice.
Electrophysiological assessment of muscle force and
motor unit number
Hind limb muscle force of female mice was assessed in vivo under
general anaesthetic at 120 days of age. The animals were
anaesthetised with 4.5% chloral hydrate (1 ml/100 g body weight)
injected intraperitoneally (Sigma-Aldrich) and prepared for
electrophysiological assessment of hind limb isometric muscle
force. The distal tendons of the TA and EDL muscles in both hind
limbs were exposed, dissected free from surrounding tissue and
cut. The sciatic nerve was exposed in the mid-thigh region, and
sectioned along with all of its branches except the deep peroneal
nerve, which innervates the TA and EDL muscles. The hind limbs
of the animal were rigidly secured to the table with stainless steel
pins and the distal tendons of the TA and EDL attached to an
isometric force transducer (Dyamometer UFI Devices, Welwyn
Garden City, UK) via silk thread. The length of each muscle was
adjusted to obtain maximal twitch tension. The muscles and
nerves were kept moist with saline and experiments were carried
out at approximately 22uC. Muscle contractions were elicited by
stimulation of the sciatic nerve via platinum electrodes. Maximal
tetanic contraction, was assessed by stimulating the sciatic nerves
of both hind limbs with trains of stimuli at increasing frequencies
of 40, 80 and 100 Hz for a total duration of 450 ms. The tetanic
tension was measured with the aid of a computer and appropriate
software (Picoscope, Pico Technology Limited). To determine the
number of functional motor units in EDL muscle, stimuli of
increasing intensity were applied to the sciatic nerve. This gradual
increase in intensity resulted in stepwise increments in twitch
tension due to successive recruitment of motor axons. The motor
unit traces were recorded on a storage oscilloscope (Tektronix,
Beaverton, OR, USA). The number of increments in twitch
tension was counted to give an estimate of the number of motor
axons present in the nerve.
Histological assessment of motor neuron survival
At the end of the acute electrophysiological experiment, female
animals were terminally anaesthetised with an overdose of chloral
hydrate and perfused transcardially with 0.9% saline followed by
4% paraformaldehyde (PFA). The spinal cords were removed and
the lumbar region (L2–L6) post-fixed overnight in PFA, and then
cryoprotected in sucrose (30% in PBS) at 4uC. Serial transverse
sections of spinal cord (20 mm) were cut on a cryostat, mounted
onto poly-lysine coated slides and stained with gallocyanin, a Nissl
stain. The sections were then dehydrated in increasing concen-
trations of alcohol, cleared in histoclear and then coverslips were
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mounted onto slides using DPX as a mounting solution. The
number of motor neurons in the sciatic motor pool was assessed by
counting the number of Nissl-stained motor neurons in every third
spinal cord section in order to avoid counting the same cell twice
in consecutive sections, using a light microscope (Leica, DMR). 40
spinal cord sections were assessed for each animal. Only large
polygonal neurons with a distinguishable nucleus and nucleolus,
visible at high magnification were included in the counts. This
method of counting has previously been used to assess motor
neuron survival [11,33].
Tissue preparation
At the end of the acute electrophysiological experiment, the
TA and EDL muscles were removed from each hindlimb of
male mice and weighed. In addition, in some animals, whole
spinal cords were collected, snap-frozen in liquid nitrogen and
stored at 270uC until being processed. They were then
weighed, thawed by addition of PBS containing 5% protease
inhibitor cocktail (Sigma-Aldrich) to a 1:15 w/v ratio and
homogenised by hand using an eppendorf-tube size pestle with
subsequent sonication of the initial lysate until fully homoge-
neous. Lysates were then pre-cleared by brief centrifugation and
used further for Western blotting, immunoprecipitation or
differential sedimentation experiments.
Assessment of bodyweight and lifespan
Male WT, hHSJ1a, G93A and DBLE mice were weighed at
least twice weekly from 40 days of age until each G93A or DBLE
mouse had lost 15% of their bodyweight, at which point they were
humanely killed. After the last remaining G93A or DBLE mouse
of each litter had lost 15% bodyweight all remaining mice of the
litter were also humanely killed.
Differential sedimentation
Pre-cleared cell or tissue lysate of 200 ml was subjected to first,
slow centrifugation of 16,000 g at room temperature for 15
minutes resulting in supernatant-1 (S1, ‘soluble’) and pellet-1 (P1)
fractions. An aliquot of S1 fraction was mixed with 46SDS-PAGE
sample buffer for future analysis while P1 was washed with 200 ml
of lysis buffer and reconstituted in buffer containing 5% SDS by
sonication with subsequent heating 98uC for 3 minutes. It was
centrifuged at 225,000 g for 30 minutes at 4uC resulting in P2 and
S2 fractions accordingly. The ‘insoluble’ P2 fraction was
reconstituted in 26SDS-PAGE sample buffer by sonication and
boiling prior to analysis by Western blotting.
SDS-PAGE, Western blotting and immunodetection
Protein lysates were mixed with 46SDS-PAGE sample buffer
containing (reducing conditions) or lacking (non-reducing
conditions) 5% b-mercaptoethanol (Sigma-Aldrich) and subject-
ed to SDS-PAGE. Proteins were then transferred to Protran
nitrocellulose membranes by Western blotting using semi-dry
transfer apparatus (Bio-Rad). Nitrocellulose membranes were
blocked with 5% non-fat dried milk with 0.1% (v/v) Tween-20
in PBS for 1 h at RT or at 4uC overnight. Membranes were
then incubated with appropriate primary (S653 1:3000; SOD-
100 1:2000; C4F6 - 1:3000; pan-Ub 1:1000; TUB2.1 1:2000)
and secondary HRP-conjugated antibodies (Perbio Science UK,
Cramlington, Northumberland, UK) and signal was detected
using ECLplus reagents (GE Healthcare, Chalfont St Giles,
Buckinghamshire, UK) and X-ray film (Fuji Medical UK,
Bedford, Bedfordshire, UK). Films were processed using a
Konica-Minolta developer.
Densitometry
Densitometry of Western blots was performed using an EPSON
Perfection V350 photo scanner with manufacturer’s software.
Developed films were scanned and the average pixel density (OD)
for each band was measured using ImageJ software. The OD of an
area devoid of bands was subtracted from the values obtained for
bands of interest in order to normalize OD against background.
Relative expression was determined by dividing the normalized
OD of bands of interest by the OD of mouse HSJ1a bands or as a
percentage of b-tubulin bands intensity as specified for each
experiment.
Immunoprecipitation (IP) and co-IP
400 ml of protein lysate was incubated with 25 ml of protein-G
Dynabeads (Invitrogen) and capture antibody (S653 2 ml; C4F6
1 ml; anti-GFP 1 ml; 9E10 1 ml) for 1 h at room temperature or
overnight at 4uC on a rotating wheel. Precipitated material was
eluted from beads by heating for 3 min at 98uC in 30 ml of
46SDS-PAGE sample buffer and subjected to SDS-PAGE and
Western blotting with antibodies against pulled-out protein (IP) or
proteins it has formed a complex with (co-IP).
Immunostaining
For immunostaining, 10 mm serial lumbar spinal cord sections
were cut on a cryostat. Sections were briefly incubated in PBS
0.1% Triton X-100 plus 3% H2O2 and then blocked in PBS
containing 0.1% Triton x-100 and 5% serum, before exposure to
primary antibody diluted in blocking solution ((16321 1:100;
SOD-100 1:200; SEDI 1:500) and appropriate secondary antibody
(1:100 v/v with block) and then developed using diamino
benzidine (DAB). For immunofluorescence, spinal cord cryosec-
tions were rehydrated in PBS and permeabilised by incubation in
PBS with 0.5% Triton-X100 (v/v) for 10 min. After being washed
twice for 10 min in PBS, sections were blocked for 40 min at room
temperature in blocking solution (10% FCS (w/v), 0.1% Triton-
X100 (v/v), 3% normal donkey serum (Sigma-Aldrich) in
DMEM/F12). Primary antibody (SEDI 1:100; b-III-tubulin
1:500; pan-Ub 1:200) was diluted in blocking solution and
incubated with sections at 4uC overnight. Sections were then
washed twice in PBS for 15 min and incubated for 1 h at room
temperature in fluorophore-conjugated donkey secondary anti-
body from Jackson ImmunoResearch (Stratech, Newmarket,
Suffolk, UK) in blocking solution. After washing twice with PBS,
sections were stained with DAPI (Sigma-Aldrich) and mounted
using fluorescent mounting media (Sigma-Aldrich) and cover slides
(VWR). Images were captured using a Zeiss LSM700 confocal
microscope with ZEN software.
Cell culture, plasmids and transfection
To produce GFP-tagged SOD1 (GFP-SOD1), SOD1-WT and
SOD1-G93A were amplified from pTRE-SOD1-WT-CFP and
pTRE-SOD1-G93A-CFP (gift from Rick Morimoto, Northwest-
ern University, USA) using SOD1 specific primers engineered to
introduce restriction endonuclease sites (Eco RI and Bam HI).
DNA was initially ligated into a pGEM-T vector (Promega,
Southampton, Hampshire, UK) before ligation into the pEGFP
C1 vector (Clontech, Mountain View, California, USA). Human
neuroblastoma SK-N-SH cells (ECACC, Porton Down, UK;
catalogue number 86012802) were maintained at 37uC and 5%
CO2 for 24 hrs in DMEM/F12 containing 10% FCS from Gibco,
(Life Technologies Ltd, Paisley, Renfrewshire, UK) and 50 mg/ml
gentamicin (Gibco) to reach 70% confluency in 6 well plates (BD
Falcon, Oxford, Oxfordshire, UK) or 8 well chamber slides
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(VWR, Lutterworth, Leicestershire, UK). Cells were then
transfected with 1 mg/well of total DNA which was a 1:1
mixture of pEGFP-SOD1 (WT or G93A mutant) and pCMV-
Tag3a-HSJ1a (wild type, H31Q or UIM mutants described
previously [24,25]) or empty vector using Lipofectamine and
Plus reagents from Invitrogen (Life Technologies Ltd, Paisley,
Renfrewshire, UK) according to manufacturer’s instructions.
For SOD1 ubiquitylation experiments, the plasmid DNA ratio
was 2:1:2 of pEGFP-SOD1, pCMV-Tag3a-HSJ1a and pCW7-
myc-Ub respectively. Cells were treated with 50 mM MG132
proteasome inhibitor (Enzo Life Sciences, Plymouth, UK) or
DMSO vehicle for 4 hours prior to lysis. 24 hrs post transfection
cells were lysed in 200 ml/well of RIPA buffer containing 5% of
protease inhibitor cocktail (Sigma-Aldrich), sonicated 365
seconds on ice, cleared, and used for immuno-precipitation or
differential sedimentation. Cells in chamber slides were fixed
with 4% paraformaldehyde and used for inclusion counts on
Nikon Eclipse 80i epi-fluorescence microscope (Nikon UK Ltd.,
Kingston Upon Thames, Surrey, UK). Images were taken using
a Zeiss LSM 700 confocal microscope (Carl Zeiss UK,
Cambridge, Cambridgeshire, UK).
Statistical analysis
Statistical significances were calculated using ANOVA incor-
porating a Student Newman Kreuls multiple comparisons test.
Significance was set at p,0.05.
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